Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia

Josep Maria Ribera, Mireia Morgades, Pau Montesinos, Rodrigo Martino, Pere Barba, Beatriz Soria, Arancha Bermúdez, María José Moreno, José González-Campos, Susana Vives, Cristina Gil, Eugenia Abella, Ramon Guàrdia, Daniel Martínez-Carballeira, Pilar Martínez-Sánchez, María Luz Amigo, Santiago Mercadal, Alfons Serrano, Aurelio López-Martínez, Ferran Vall-LloveraMaría José Sánchez-Sánchez, María Jesús Peñarrubia, María Calbacho, Jose Angel Méndez, Juan Bergua, Antonia Cladera, Mar Tormo, Daniel García-Belmonte, Evarist Feliu, Juana Ciudad, Alberto Orfao

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Abstract

© 2017, © 2017 Informa UK Limited, trading as Taylor & Francis Group. Native or pegylated (PEG) asparaginase (ASP) are commonly used in treatment of acute lymphoblastic leukemia (ALL), but have been scarcely compared in the same trial in adult patients. Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL. Ninety-one patients received native ASP and 35 PEG-ASP in induction. No significant differences were observed in complete remission, minimal residual disease levels after induction and after consolidation, disease-free survival, and overall survival. No significant differences in grades 3–4 toxicity were observed in the induction period, although a trend for higher hepatic toxicity was observed in patients receiving PEG-ASP. In this trial the type of ASP did not influence patient response and outcome.
Original languageEnglish
Pages (from-to)1634-1643
JournalLeukemia and Lymphoma
Volume59
Issue number7
DOIs
Publication statusPublished - 3 Jul 2018

Keywords

  • Adult acute lymphoblastic leukemia
  • Escherichia coli asparaginase
  • efficacy
  • native
  • pegylated
  • toxicity

Fingerprint Dive into the research topics of 'Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this